ArticleArchives of general psychiatry2006

Outcomes, costs, and policy caution. A commentary on: the Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

Robert A RosenheckPubMed ↗Publisher ↗

No numbers read from the abstract.